Literature DB >> 18445772

Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC.

Shanna Arnold1, Emilia Mira, Sabeeha Muneer, Grzegorz Korpanty, Adam W Beck, Shane E Holloway, Santos Mañes, Rolf A Brekken.   

Abstract

Pancreatic adenocarcinoma is characterized by desmoplasia, local invasion, and metastasis. These features are regulated in part by MMP9 and SPARC. To explore the interaction of SPARC and MMP9 in cancer, we first established orthotopic pancreatic tumors in SPARC-null and wild-type mice with the murine pancreatic adenocarcinoma cell line, PAN02. MMP9 expression was higher in tumors from wild-type compared to SPARC-null mice. Coincident with lower MMP9 expression, tumors grown in SPARC-null mice were significantly larger, had decreased ECM deposition and reduced microvessel density compared to wild-type controls. In addition, metastasis was enhanced in the absence of host SPARC. Therefore, we next analyzed the orthotopic tumor growth of PAN02 cells transduced with MMP9 or a control empty vector. Forced expression of MMP9 by the PAN02 cells resulted in larger tumors in both wild-type and SPARC-null animals compared to empty vector controls and further diminished ECM deposition. Importantly, forced expression of MMP9 within the tumor reversed the decrease in angiogenesis and abrogated the metastatic potential displayed by control tumors grown in SPARC-null mice. Finally, contrary to the in vivo results, MMP9 increased cell migration in vitro, which was blocked by the addition of SPARC. These results suggest that SPARC and MMP9 interact to regulate many stages of tumor progression including ECM deposition, angiogenesis and metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445772      PMCID: PMC2459223          DOI: 10.3181/0801-RM-12

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  47 in total

1.  Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.

Authors:  Rolf A Brekken; Pauli Puolakkainen; David C Graves; Gail Workman; Sharon R Lubkin; E Helene Sage
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

2.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.

Authors:  Yuki Hamano; Michael Zeisberg; Hikaru Sugimoto; Julie C Lively; Yohei Maeshima; Changqing Yang; Richard O Hynes; Zena Werb; Akulapalli Sudhakar; Raghu Kalluri
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

3.  SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells.

Authors:  Tsuyoshi Fujita; Hideki Shiba; Masatoshi Sakata; Yuushi Uchida; Shigeo Nakamura; Hidemi Kurihara
Journal:  J Oral Pathol Med       Date:  2002-07       Impact factor: 4.253

4.  Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis.

Authors:  E Helene Sage; May Reed; Sarah E Funk; Thao Truong; Melissa Steadele; Pauli Puolakkainen; Donald H Maurice; James A Bassuk
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

5.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Rolf A Brekken; Efthimios Sivridis; Kevin C Gatter; Adrian L Harris; E Helene Sage
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

Review 6.  Pancreatic cancer.

Authors:  Donghui Li; Keping Xie; Robert Wolff; James L Abbruzzese
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

7.  SPARC deficiency leads to early-onset cataractogenesis.

Authors:  K Norose; J I Clark; N A Syed; A Basu; E Heber-Katz; E H Sage; C C Howe
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-12       Impact factor: 4.799

8.  Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment.

Authors:  Christophe F Chantrain; Hiroyuki Shimada; Sonata Jodele; Susan Groshen; Wei Ye; David R Shalinsky; Zena Werb; Lisa M Coussens; Yves A DeClerck
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

Review 9.  Axis of evil: molecular mechanisms of cancer metastasis.

Authors:  Thomas Bogenrieder; Meenhard Herlyn
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

10.  SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.

Authors:  Norihiro Sato; Noriyoshi Fukushima; Naoki Maehara; Hiroyuki Matsubayashi; Jens Koopmann; Gloria H Su; Ralph H Hruban; Michael Goggins
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

View more
  30 in total

Review 1.  SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.

Authors:  Ferda Kaleağasıoğlu; Martin R Berger
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 2.  Anti-cancer role of SPARC, an inhibitor of adipogenesis.

Authors:  Ganji Purna Chandra Nagaraju; Dipali Sharma
Journal:  Cancer Treat Rev       Date:  2011-01-14       Impact factor: 12.111

3.  Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristina Y Aguilera; Huocong Huang; Wenting Du; Moriah M Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B Fleming; Diego H Castrillon; Xiaomei Ren; Ke Ding; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

4.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

5.  Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing.

Authors:  Amy D Bradshaw; Catalin F Baicu; Tyler J Rentz; An O Van Laer; D Dirk Bonnema; Michael R Zile
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

6.  Effect of chronic morphine on the dentate gyrus neurogenic microenvironment.

Authors:  A A Arguello; S J Fischer; J R Schonborn; R W Markus; R A Brekken; A J Eisch
Journal:  Neuroscience       Date:  2009-01-19       Impact factor: 3.590

Review 7.  Recruitment and retention: factors that affect pericyte migration.

Authors:  Kristina Y Aguilera; Rolf A Brekken
Journal:  Cell Mol Life Sci       Date:  2013-08-04       Impact factor: 9.261

8.  Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium.

Authors:  Hiroe Toba; Lisandra E de Castro Brás; Catalin F Baicu; Michael R Zile; Merry L Lindsey; Amy D Bradshaw
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-05-03       Impact factor: 4.310

9.  The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S S Lakka
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.